Skip to main content

Table 1 Safety and efficacy of combination treatment in patients with advanced HCC

From: Emerging agents and regimens for hepatocellular carcinoma

Combinations

Number of patients

ORR (RECIST v1.1)

Median PFS (months)

Grade 3/4 AE

Reference

Apatinib + camrelizumab

16 (second line)

50%

5.8

NA

Xu et al. [54]

Lenvatinib + pembrolizumab

30 (26/30 as first line)

53.3%

9.7

NA

Kudo [81]

Bevacizumab + atezolizumab

68 (first line)

34%

14.9

25%

Pishvaian et al. [82]

Durvalumab + tremelimumab

40 (first and second line)

25%

NA

25%

Kelley et al. [83]

Ipilimumab + nivolumab

148 (second line)

31%

NA

37%

Yau et al. [65]

Axitinib + avelumab

22 (first line)

13.6%

5.5

72.7%

Kudo et al. [84]

FOLFOX4 + camrelizumab

34 (first line)

26.5%

5.5

5.9%

Qin et al. [85]

  1. ORR objective response rate, PFS progression-free survival, AE adverse events, NA not available